Live Biotherapeutics Market to Grow with a CAGR of 14.06% through 2030
Increasing
investment in microbiome-based therapeutic research and growing demand for
personalized probiotic treatments, is expected to drive the Global Live
Biotherapeutics Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “Live Biotherapeutics Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2030F”,
the Global Live Biotherapeutics Market stood at USD 112.34 Million in 2024 and is
expected to reach USD 247.69 Million by 2030 with a CAGR of 14.06% during the forecast
period. The Global Live
Biotherapeutics Market is experiencing accelerated growth driven by the growing
number of clinical-stage microbiome-based therapies across therapeutic areas
including dermatology, neurology, and immunology. Pharmaceutical firms are
moving beyond traditional probiotic applications and investing heavily in
genetically engineered live biotherapeutic strains that can deliver targeted
therapeutic payloads. Rising incidence of antibiotic-resistant infections has
intensified the search for alternative treatment modalities, further fueling
interest in live biotherapeutic products (LBPs). Government-funded microbiome
research programs and rising support for precision medicine have added momentum
to this shift. Investors are showing growing interest in early-stage biotech
firms working in the live biotherapeutics domain, reflecting increased
confidence in the market’s long-term viability.
The
contract development and manufacturing segment is being reshaped by the
increasing demand for customized microbial manufacturing, including single-use
bioreactor systems, aseptic fill-finish solutions, and lyophilization of live
organisms. CDMOs with specialized bio-manufacturing capabilities are witnessing
greater engagement from pharma firms seeking scalable and compliant solutions.
This has encouraged facility expansions and adoption of digital manufacturing
tools like electronic batch records and real-time process monitoring.
Collaborations between CDMOs and synthetic biology firms are also emerging,
enabling next-generation strain engineering and accelerated product
development. As regulatory agencies encourage early dialogue, sponsors are
actively engaging CDMOs earlier in the clinical development process to navigate
complex compliance landscapes.
There
is significant untapped potential in pediatric, geriatric, and
immunocompromised patient groups where conventional therapies may be less
effective or poorly tolerated. Emerging research indicating microbiome
influence on vaccine response and drug metabolism could open avenues for live
biotherapeutics in personalized medicine. Strategic expansions by CDMOs into
emerging markets with local fermentation capabilities and GMP-compliant
infrastructure are poised to enhance global accessibility. Demand for over-the-counter
live microbial formulations for wellness and preventive health also presents an
opportunity for diversification beyond prescription therapeutics. These trends
position the market for sustainable expansion across therapeutic, demographic, and
geographic dimensions.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Live Biotherapeutics Market”
The Global Live
Biotherapeutics Market is segmented into application, product, type of formulation,
scale of operation, regional distribution, and company.
Based on the Scale
of Operation, Clinical Scale Operations emerged as the fastest growing segment
in the Global Live Biotherapeutics Market during the forecast period. As live biotherapeutics progress from
preclinical trials to human clinical trials, the need for clinical-scale
manufacturing has surged. Clinical-scale operations involve the production of
therapeutic products in larger quantities while maintaining the necessary
control and validation to meet regulatory requirements. This scaling up is
crucial for advancing therapeutic candidates toward commercialization. The
transition to clinical scale is driven by the increasing number of live
biotherapeutic products progressing through the clinical trial phases,
particularly those focusing on microbiome-based and genetically engineered
therapies. As these products undergo clinical trials, the demand for efficient,
reliable manufacturing at clinical scale has become a key factor in their
success.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
Live Biotherapeutics Market during
the forecast period. This is due to the growing investment in biotechnology,
the increasing prevalence of chronic diseases in the Asia-Pacific region. With
a rapidly aging population in several countries and an increased focus on
improving healthcare outcomes, the demand for alternative therapies like live
biotherapeutics is rising. Consumers and healthcare providers are turning to
microbiome-based treatments as a viable solution to various health issues,
providing a significant market opportunity for CDMOs specializing in this
field. Moreover, Asia-Pacific's competitive advantage lies in its ability to
produce live biotherapeutic products at scale and cost-effectively, which is
further accelerated by the region’s manufacturing capabilities and expertise.
As a result, Asia-Pacific’s rapid development in clinical-scale operations and
the region's emergence as a hub for research and manufacturing make it the
fastest-growing region in the Global Live Biotherapeutics Market during the
forecast period.
Major
companies operating in Global Live Biotherapeutics Market are:
- Arrant
Bio
- 4D
Pharma
- Cerbios
- Biose
Industrie
- Assembly
Biosciences, Inc.
- Wacker
Chemie AG
- Quay
Pharmaceuticals
- NIZO
- Lonza
- Inpac
Probiotics
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Global Live Biotherapeutics Market
is expanding due to the rising emphasis on sustainable and eco-friendly
manufacturing practices in the production of live biotherapeutics. Companies
are increasingly adopting green manufacturing techniques, such as using
renewable resources and minimizing waste, to align with global environmental
standards and reduce their carbon footprint. The growing consumer preference
for environmentally conscious products is prompting CDMOs (Contract Development
and Manufacturing Organizations) to adopt these practices in their operations.
These efforts not only contribute to sustainability goals but also help
companies meet regulatory requirements and enhance the appeal of their products
in a competitive market.,” said Mr. Karan Chechi, Research Director of TechSci
Research, a research-based management consulting firm.
“Live Biotherapeutics
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
Segmented By Application (C.difficle, Crohns disease, IBS, Diabetes, Others),
By Product (APIs, FDFs), By Type of Formulation (Solid Formulations, Oral
Liquids, Injectables, Others), By Scale of Operation (Preclinical Scale
Operations, Clinical Scale Operations, Commercial Scale Operations), By Region
and Competition, 2020-2030F”, has evaluated the future growth potential of Global
Live Biotherapeutics Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Live
Biotherapeutics Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com